ROE
33.0%
✅ ROE 33.0% clears the 15% quality threshold; stability over 3–5 years is not available in this feed.
NASDAQ · Healthcare · Large Cap · Mkt cap $3.9B · Vol 814.0K
$74.56
▼ -7.69% today
Live · market · updated 10:06:00 PM
Day $72.03–$75.53 · 52w $15.22–$90.87
Research CareDx, Inc. (NASDAQ: CDNA) using available valuation, profitability and leverage data. Check each figure's source and compare reporting periods before drawing conclusions. Missing provider data must not be treated as a reported company fact.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Source: Yahoo Finance — CareDx, Inc. company profileCompany website
Available ratios are snapshots. This page does not provide a complete historical quarterly-results, profit-and-loss, balance-sheet or shareholding series. Use company filings to verify reporting periods, accounting changes and trends.
Weighted 13-factor score / 100
CareDx, Inc. scores 63/100 on the DeepScreen quality-and-value model. Growth is running near 39.3% with a PEG of 0.03, ROCE of 15.7% and debt/equity at 0.06x. Quality and price roughly offset each other; wait for a better entry or clearer growth.
Vision & Utility score and Secret Tips badges is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Target price, trim level & stop-loss is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
The 63/100 score is a weighted average of 13 fundamental factors. This panel shows which factor scores contribute most to the current model result.
Undervalued vs. growth. Weighted contribution: 12.5 points.
Excellent shareholder returns. Weighted contribution: 10.2 points.
Conservative balance sheet. Weighted contribution: 8.6 points.
Very low structural debt. Weighted contribution: 6.3 points.
Low for the sector. Weighted contribution: 0.4 points.
High multiple — priced for exceptional growth. Weighted contribution: 0.5 points.
Low fixed-cost gearing. Weighted contribution: 1.3 points.
Rich sales multiple. Weighted contribution: 2.2 points.
Factor scores are model outputs, not forecasts. A high or low factor score describes how that metric is treated by the DeepScreen rules; review the underlying value and its source before drawing a broader conclusion.
Current operating, capital-efficiency and cash-flow metrics using the latest available provider data.
Provider-reported period-over-period growth
Provider-reported period-over-period growth
Return on equity
Return on capital employed
Net income as a share of revenue
Debt relative to shareholder equity
189% of operating cash flow
Cash $250.5M · Debt $29.0M
Provider periods can differ by field. Growth figures are presented as reported by the upstream provider; they are not reconstructed from an expensive historical time series.
Threshold-based research checks from the latest available fundamentals. These are on-page signals, not push notifications or predictions.
ROE is 33.0% while ROA is 0.9%. Check whether leverage is amplifying equity returns.
Free cash flow is 189% of operating cash flow in the latest provider snapshot.
Signals are intended to highlight questions for research, not replace company filings or independent review.
Industry match: Diagnostics & Research. Peers use the same regional market universe, same sector, provider-reported industry where available, and market-cap proximity.
Peer fundamentals are still loading. The comparison will populate automatically when comparable company data arrives.
DeepScreen Secret Tips, traps & X-Ray analysis is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Accounting quality and solvency screens. Anything that can't be computed from available filings data is left blank rather than estimated.
Piotroski F-Score
7/87
7 of 8 financial-health checks passed (1 checks need data this provider doesn't publish).
Altman Z-Score
Insufficient data—
Needs total assets, operating profit and debt — not published for this listing yet.
Beneish (earnings quality)
Watch accruals0.54
Accrual-quality check only: operating cash flow is 54% of reported net profit. Below 80% means profits aren't fully backed by cash.
Scores are free. The criteria-by-criteria breakdown — exactly which checks this company failed — is part of DeepScreen Pro.
P/E Ratio (TTM)
Live31.5x
Fairly priced
Price divided by earnings per share: how much you pay today for ₹1/$1 of annual profit. Only compare within the same industry.
PEG Ratio
LivePro
Advanced ratio · DeepScreen Pro
Pro
P/S Ratio
Live7.88x
Rich sales multiple
Price relative to revenue. Sales are much harder to accounting-fudge than earnings, so this is a trustworthy number — and it's often the only usable multiple for loss-making or early-stage companies where P/E doesn't exist. But revenue without margin means nothing on its own: always read it alongside net margin.
P/B Ratio
Live8.37x
Typical for the sector
Price versus net asset value. Asset-light businesses like this one carry most of their value in people and IP, not machinery or property, so P/B runs structurally high here — not a red flag by itself. Weigh P/E and ROE more heavily instead.
EV/Revenue
LivePro
Advanced ratio · DeepScreen Pro
Pro
EV/EBITDA
LivePro
Advanced ratio · DeepScreen Pro
Pro
ROE
Live33.0%
Excellent shareholder returns
Return on shareholder equity. High ROE is great — unless it is manufactured by heavy debt, so always read it next to ROA and D/E: high ROE with low ROA is the classic debt-trap pattern.
ROA
Live0.9%
Low for the sector
Net Income / Total Assets — how efficiently the whole business converts its asset base into profit. Computed as ROE / (1 + D/E) when live data is unavailable. Only compare within the same industry: asset-light businesses (IT, services) will always show a structurally higher ROA than asset-heavy ones (steel, airlines, utilities) simply because they carry far less on the balance sheet to begin with, not because they're better run.
ROCE
Modeled15.7%
Solid
Return on all capital employed (equity plus debt). The cleanest quality signal because debt cannot flatter it.
Debt / Equity
Live0.06x
Conservative balance sheet
Total liabilities divided by shareholders' equity — the broadest leverage measure. High leverage boosts ROE in good years and destroys it in bad ones.
LT Debt / Equity
ModeledPro
Advanced ratio · DeepScreen Pro
Pro
Payout Ratio
Live0%
Full reinvestment — no dividend
Share of profit paid out as dividend. Above 100% means the company is funding the dividend from debt or reserves, not profit — a genuine red flag, not just 'high'. 30–60% is the classic sustainable balance; well below that usually just means a growth company reinvesting rather than anything wrong.
Operating Leverage
Modeled1.12x
Low fixed-cost gearing
How much profit jumps for each 1% of extra sales — driven by how much of the cost base is fixed (rent, salaries) versus variable (raw materials). It's a double-edged sword: high fixed-cost businesses (manufacturing, airlines, software) see profit jump disproportionately as sales grow, but the same fixed costs turn a small sales dip into an outsized loss. That's also why these businesses tend to lead in a bull market and get hit hardest first when demand turns down.
DCF & Graham intrinsic value calculators is a DeepScreen Pro feature
Unlock from ₹50/week · ₹175/month · ₹1800/year
Figures use live Yahoo Finance data where available; any field Yahoo doesn't report falls back to the DeepScreen model.
Loading live headlines…
Review the scoring factors, underlying data and limitations before comparing companies.
Read the methodology